Metrics to compare | 299660 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship299660PeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −3.4x | −0.2x | |
PEG Ratio | 0.00 | 0.03 | 0.00 | |
Price/Book | 0.0x | 2.2x | 2.6x | |
Price / LTM Sales | 0.0x | 5.6x | 2.7x | |
Upside (Analyst Target) | - | 15.2% | 72.2% | |
Fair Value Upside | Unlock | 26.5% | 12.4% | Unlock |
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.